DSC
BBC icon

Duncker Streett & Co’s Virtus Biotech Clinical Trials ETF BBC Stock Holding History

Duncker Streett & Co’s Portfolio BBC Stock Details BBC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-752
Closed -$21.9K – 488
2024
Q1 		$21.9K Hold
752
– – ﹤0.01% 368
2023
Q4 		$18.4K Hold
752
– – ﹤0.01% 373
2023
Q3 		$14.8K Hold
752
– – ﹤0.01% 386
2023
Q2 		$18K Hold
752
– – ﹤0.01% 370
2023
Q1 		$16.5K Hold
752
– – ﹤0.01% 372
2022
Q4 		$18.8K Buy
+752
New +$18.7K ﹤0.01% 375

Other funds holding BBC

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $91.6B AUM 29.2% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return
DWS
Dynamic Wealth Strategies Granite Bay, California $188M AUM 18.55% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
HI
Harbour Investments Madison, Wisconsin $7.43B AUM 24.49% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return

Duncker Streett & Co's BBC Position: Q2 2024 in Review

Duncker Streett & Co sold out of Virtus Biotech Clinical Trials ETF (BBC) in Q2 2024, closing a stake of 752 shares — an estimated $21.9K sold.

Duncker Streett & Co first reported a position in BBC in Q4 2022 and held it in 6 quarters. The position peaked at $21.9K in Q1 2024. 14 funds tracked by Wall St. Rank hold BBC as of Q2 2024.

  • Duncker Streett & Co reported no remaining Virtus Biotech Clinical Trials ETF position as of Q2 2024 after selling out during the quarter.
  • Duncker Streett & Co sold 752 Virtus Biotech Clinical Trials ETF shares in Q2 2024, an estimated $21.9K.
  • Duncker Streett & Co first reported a position in Virtus Biotech Clinical Trials ETF in Q4 2022 and held it in 6 quarters.
  • Duncker Streett & Co's Virtus Biotech Clinical Trials ETF position peaked at $21.9K in Q1 2024.
  • 14 funds tracked by Wall St. Rank held Virtus Biotech Clinical Trials ETF as of Q2 2024.

Based on Duncker Streett & Co's 13F filing for Q2 2024, filed 31 Jul 2024.